BioWorld

Jan. 5, 2006

After Adding $25M, Novacea To Launch DN-101 Phase III

Closing the second tranche of a Series C financing begun two years ago, Novacea Inc. raised more than $25 million - money it will use to launch a Phase III trial with DN-101 to treat advanced prostate cancer. (BioWorld Today) Read More

Alcon Signs Kalypsys For Small-Molecule Research

Defense Bill Provides Funding For Research By AVI, Others

Medicure Raising C$12M In Bought Deal Financing

Other News To Note

Appointments And Advancements

Today's news in brief

BioWorld

BioWorld briefs for Jan 16, 2025.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for Jan. 16, 2026.

SERPINB1 as potential biomarker for spinocerebellar ataxia type 2

BioWorld Science

Researchers from Goethe-Universität and collaborators investigated novel molecular biomarker candidates for spinocerebellar ataxia type 2, a progressive...

Abbvie snags PD-1/VEGF bispecific in potential $5B Remegen deal

BioWorld

With rumors regarding a couple of potential mega-mergers making the rounds, the week of the annual J.P. Morgan Healthcare Conference kicked off with the official...

Illustration of human body surrounded by DNA, cell and drug icons

Cell/gene therapy sector now sustainable; China competition mounting

BioWorld

There was an upbeat message for cell and gene therapy companies in the 2026 industry update presented as the J.P. Morgan Healthcare Conference opened on Monday,...